Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Entrada Therapeutics Inc.

    NASDAQ: TRDA · Real-Time Price · USD
    8.09
    0.16 (2.02%)
    At close: Jun 05, 2025, 3:59 PM
    8.12
    0.43%
    After-hours: Jun 05, 2025, 04:04 PM EDT

    Entrada Therapeutics Statistics

    Share Statistics

    Entrada Therapeutics has 37.95M shares outstanding. The number of shares has increased by 1.26% in one year.

    Shares Outstanding

    n/a
    		 37.95M

    Shares Change (YoY)

    n/a
    		 1.26%

    Shares Change (QoQ)

    n/a
    		 0.47%

    Owned by Institutions (%)

    n/a
    		 75.32%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 155

    FTD / Avg. Volume

    n/a
    		 0.11%

    Short Selling Information

    The latest short interest is 1.06M, so 2.78% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.06M

    Short % of Shares Out

    n/a
    		 2.78%

    Short % of Float

    n/a
    		 5.14%

    Short Ratio (days to cover)

    n/a
    		 8.34

    Valuation Ratios

    The PE ratio is 9.83 and the forward PE ratio is -1.87. Entrada Therapeutics's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 9.83

    Forward PE

    n/a
    		 -1.87

    PS Ratio

    n/a
    		 3.06

    Forward PS

    n/a
    		 0.7

    PB Ratio

    n/a
    		 1.5

    P/FCF Ratio

    n/a
    		 -14.43

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Entrada Therapeutics has an Enterprise Value (EV) of 603.02M.

    EV / Sales

    n/a
    		 2.86

    EV / EBITDA

    n/a
    		 12.83

    EV / EBIT

    n/a
    		 -14.51

    EV / FCF

    n/a
    		 -13.49

    Financial Position

    The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.14.

    Current Ratio

    n/a
    		 11.15

    Quick Ratio

    n/a
    		 11.15

    Debt / Equity

    n/a
    		 0.14

    Debt / EBITDA

    n/a
    		 1.26

    Debt / FCF

    n/a
    		 -1.32

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 15.31% and Return on Invested Capital is 9.39%.

    Return on Equity

    n/a
    		 15.31%

    Return on Assets

    n/a
    		 12.47%

    Return on Invested Capital

    n/a
    		 9.39%

    Revenue Per Employee

    n/a
    		 $1,151,814.21

    Profits Per Employee

    n/a
    		 $358,612.02

    Employee Count

    n/a
    		 183

    Asset Turnover

    n/a
    		 0.4

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 859K

    Effective Tax Rate

    n/a
    		 1.29%

    Stock Price Statistics

    The stock price has increased by -48.8% in the last 52 weeks. The beta is -0.06, so Entrada Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.06

    52-Week Price Change

    n/a
    		 -48.8%

    50-Day Moving Average

    n/a
    		 8.37

    200-Day Moving Average

    n/a
    		 13.78

    Relative Strength Index (RSI)

    n/a
    		 48.7

    Average Volume (20 Days)

    n/a
    		 139,987

    Income Statement

    In the last 12 months, Entrada Therapeutics had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.

    Revenue

    n/a
    		 210.78M

    Gross Profit

    n/a
    		 207.01M

    Operating Income

    n/a
    		 47.01M

    Net Income

    n/a
    		 65.63M

    EBITDA

    n/a
    		 47.01M

    EBIT

    n/a
    		 47.01M

    Earnings Per Share (EPS)

    n/a
    		 1.76
    Full Income Statement

    Balance Sheet

    The company has 101.21M in cash and 59.21M in debt, giving a net cash position of 42M.

    Cash & Cash Equivalents

    n/a
    		 101.21M

    Total Debt

    n/a
    		 59.21M

    Net Cash

    n/a
    		 42M

    Retained Earnings

    n/a
    		 -129.34M

    Total Assets

    n/a
    		 486.48M

    Working Capital

    n/a
    		 384.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -41.56M and capital expenditures -3.16M, giving a free cash flow of -44.72M.

    Operating Cash Flow

    n/a
    		 -41.56M

    Capital Expenditures

    n/a
    		 -3.16M

    Free Cash Flow

    n/a
    		 -44.72M

    FCF Per Share

    n/a
    		 -1.2
    Full Cash Flow Statement

    Margins

    Gross margin is 98.21%, with operating and profit margins of 22.3% and 31.13%.

    Gross Margin

    n/a
    		 98.21%

    Operating Margin

    n/a
    		 22.3%

    Pretax Margin

    n/a
    		 31.54%

    Profit Margin

    n/a
    		 31.13%

    EBITDA Margin

    n/a
    		 22.3%

    EBIT Margin

    n/a
    		 22.3%

    FCF Margin

    n/a
    		 -21.21%

    Dividends & Yields

    TRDA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 10.17%

    FCF Yield

    n/a
    		 -6.93%
    Dividend Details

    Analyst Forecast

    The average price target for TRDA is $28, which is 246.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $28

    Price Target Difference

    n/a
    		 246.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 21.33

    Graham Upside

    n/a
    		 163.66%

    Scores

    Altman Z-Score

    n/a
    		 3.5

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist